Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vetropolycin HC is a veterinary ophthalmic ointment developed by Dechra Veterinary Products for topical ocular treatment of bacterial infections and associated inflammation in dogs and cats. It is a fixed-dose combination of three **small molecule** antibiotics\u2014bacitracin zinc, neomycin sulfate, and polymyxin B sulfate\u2014plus the corticosteroid hydrocortisone acetate. Bacitracin primarily disrupts bacterial cell wall synthesis in susceptible gram-positive organisms, neomycin is an aminoglycoside that inhibits bacterial protein synthesis through ribosomal binding, and polymyxin B disrupts the outer membrane of susceptible gram-negative bacteria; hydrocortisone acetate provides local anti-inflammatory glucocorticoid activity. The product is FDA-approved for veterinary use and is indicated for acute or chronic conjunctivitis and superficial infections of the eyelid and conjunctiva caused by organisms susceptible to the included antibiotics.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Vetropolycin HC.